Axelar AB:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Axelar AB - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3032
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:18
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Axelar AB (Axelar) is a drug development company that develops various novel anti-cancer treatments. The company lead drug candidateAXL1717 is used for the treatmentof non-small cell lung cancer. It also offers treatments for disease such as glioblastoma, sarcoma, malignant melanoma and multiple myeloma, and others. Axelar conducts research on inhibitors of insulin-like growth factor-1 receptor and their applications in human diseases. The company develops drugs in therapeutic areas including non-small cell lung cancer such as squamous cell carcinoma and adenocarcinoma. Axelar is headquartered in Solna, Sweden.

Axelar AB – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Axelar AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Axelar AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Axelar AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Axelar AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Axelar AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Axelar AB, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Axelar Enters into Co-Development Agreement with Cadila Pharma 10
Acquisition 11
Ostersjostiftelsen Acquires Stake in Axelar from Karolinska Development 11
BrainsToVentures And Rosetta Capital Acquire Minority Stake In 13 Portfolio Companies Of Karolinska Development For US$34 Million 12
Axelar AB – Key Competitors 15
Axelar AB – Key Employees 16
Axelar AB – Locations And Subsidiaries 17
Head Office 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18

List of Tables
Axelar AB, Pharmaceuticals & Healthcare, Key Facts 2
Axelar AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Axelar AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Axelar AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Axelar AB, Deals By Therapy Area, 2012 to YTD 2018 8
Axelar AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Axelar Enters into Co-Development Agreement with Cadila Pharma 10
Ostersjostiftelsen Acquires Stake in Axelar from Karolinska Development 11
BrainsToVentures And Rosetta Capital Acquire Minority Stake In 13 Portfolio Companies Of Karolinska Development For US$34 Million 12
Axelar AB, Key Competitors 15
Axelar AB, Key Employees 16

List of Figures
Axelar AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Axelar AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Axelar AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Axelar AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Axelar AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Axelar AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Axelar AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Axelar AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Axelar AB:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Challenge Group Holdings PTE. LTD.:企業の戦略・SWOT・財務分析
    Challenge Group Holdings PTE. LTD. - Strategy, SWOT and Corporate Finance Report Summary Challenge Group Holdings PTE. LTD. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Bounty Oil & Gas NL (BUY):石油・ガス:M&Aディール及び事業提携情報
    Summary Bounty Oil & Gas NL (Bounty) is an independent exploration and production company that acquires, explores and develops oil and natural gas assets and produces oil and natural gas. It also carries out marketing of oil and gas (petroleum). The company’s Australian Onshore properties include PR …
  • Align Technology, Inc.:企業の戦略・SWOT・財務情報
    Align Technology, Inc. - Strategy, SWOT and Corporate Finance Report Summary Align Technology, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • SMRT Corporation Ltd.:企業の戦略・SWOT・財務情報
    SMRT Corporation Ltd. - Strategy, SWOT and Corporate Finance Report Summary SMRT Corporation Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Landesbank Baden-Wurttemberg:企業のM&A・事業提携・投資動向
    Landesbank Baden-Wurttemberg - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Landesbank Baden-Wurttemberg Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …
  • TOTVS S.A.:企業の戦略・SWOT・財務情報
    TOTVS S.A. - Strategy, SWOT and Corporate Finance Report Summary TOTVS S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • MSL Solutions Limited (MPW):企業の財務・戦略的SWOT分析
    MSL Solutions Limited (MPW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Prominence Energy NL (SUR):企業の財務・戦略的SWOT分析
    Summary Prominence Energy NL(Prominence Energy) formerly known as Sun Resources NL is an oil and gas exploration and development company. The company explores and develops crude oil and natural gas. Its services include exploration, production, and development of unconventional oil and gas resources …
  • Tolero Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Tolero Pharmaceuticals Inc (Tolero), a subsidiary of Dainippon Sumitomo Pharma America Holdings Inc, is a drug company that offers medicines to treat cancer and other serious human diseases. The company’s alvocidib is a cyclin dependent kinase inhibitor with selective activity against CDK9 a …
  • Lam Research Corporation:企業の戦略・SWOT・財務情報
    Lam Research Corporation - Strategy, SWOT and Corporate Finance Report Summary Lam Research Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Grenergy Renovables SL (GRE):電力:M&Aディール及び事業提携情報
    Summary Grenergy Renovables SL (Grenergy Renovables), a subsidiary of DARUAN Venture Capital SCR, is an alternative energy company that generates renewable energy through solar photovoltaic plants. The company provides services such as construction, engineering, and procurement services, project dev …
  • Midea Group Co Ltd:戦略・SWOT・企業財務分析
    Midea Group Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Midea Group Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • KSK Energy Ventures Ltd (KSK):電力:M&Aディール及び事業提携情報
    Summary KSK Energy Ventures Ltd (KSKEVL), a subsidiary of KSK Energy Ltd, is a power project development company that carries out development, operations and maintenance of power projects in India. The company operates power project at multiple phases including projects in planning phase, project un …
  • InKemia IUCT Group SA (IKM):製薬・医療:M&Aディール及び事業提携情報
    Summary InKemia IUCT Group SA (InKemia IUCT), formerly Institut Univ De Ciencia i Technology SA, is a biotechnology company. The company provides research and development, technological, and consulting services. It offers customized research services. InKemia IUCT provides technology services such a …
  • Diversicare Healthcare Services Inc (DVCR):企業の財務・戦略的SWOT分析
    Summary Diversicare Healthcare Services Inc (Diversicare), formerly Advocat Inc is a healthcare service provider that offers post acute care services and short term rehabilitation and long-term care services to nursing home patients. The company’s services include life steps rehabilitation program, …
  • ABC arbitrage SA (ABCA):企業の財務・戦略的SWOT分析
    ABC arbitrage SA (ABCA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Parex Resources Inc (PXT):石油・ガス:M&Aディール及び事業提携情報
    Summary Parex Resources Inc (Parex) is an oil and gas exploration and development company that acquires, explores, develops and produces crude oil and natural gas in South America and the Caribbean. The company holds interests in land base of 1.7 million gross acres over 22 blocks in Colombia's Llan …
  • Contact Energy Ltd (CEN):石油・ガス:M&Aディール及び事業提携情報
    Summary Contact Energy Ltd (Contact Energy) is an energy company that generates electricity and sells electricity, natural gas and liquefied petroleum gas to customers. It generates electricity from various sources of energy including thermal, hydro and geothermal sources of energy. It supplies elec …
  • DesignMedix Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary DesignMedix Inc (DesignMedix) is a biotechnology company that develop drugs to overcome drug resistance in multiple diseases such as malaria and diarrhea. The company develops malaria cure drugs, malaria preventive drugs and anti-bacterial drugs. It develops DM1157, a drug candidate that pro …
  • Banco Santander-Chile:企業の戦略・SWOT・財務分析
    Banco Santander-Chile - Strategy, SWOT and Corporate Finance Report Summary Banco Santander-Chile - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆